Results 151 to 160 of about 26,042 (243)

Results of Multicenter Phase II Study With Imatinib Mesylate in Allogeneic Recipients With Steroid-Refractory Chronic GVHD. [PDF]

Cell Transplant, 2022
Baek DW, Cho HJ, Kim JH, Ahn JS, Kim HJ, Lim SN, Cheong JW, Kim SY, Lee HS, Won JH, Yhim HY, Sohn SK, Moon JH.   +12 more
europepmc   +1 more source

Imatinib mesylate does not counteract ovarian tissue fibrosis in postnatal rat ovary

, 2019
Babak Asadi‐Azarbaijani, Saskia Braber, Majorie B.M. van Duursen, Kirsi Jahnukainen, Regiane R. Santos, Irma C. Oskam   +5 more
openalex   +2 more sources

The Mechanisms of Resistance to Tyrosine Kinase Inhibitor Imatinib Therapy of Chronic Myeloid Leukemia

Медицинский вестник Юга России, 2010
Imatinib mesylate is a potent and high selective inhibitor of Bcr-Abl tyrosine kinase, which is established now as the standard of Philadelphia chromosome positive (Ph) chronic myeloid leukemia (CML) treatment.
S. I. Kutsev, S. V. Mordanov, A. N. Zeltser, O. S. Oxenjuk, O. A. Ustaeva, T. I. Kungurova, E. V. Burnasheva, E. Grankina, Yu. V. Shatokhin   +8 more
doaj  

Dynein axonemal heavy chain 9 M4374I variation may have an effect on imatinib mesylate resistance in CML. [PDF]

Med Int (Lond), 2022
Yildirim MS, Şi̇mşek L, Zamani̇ AG, Çeneli̇ Ö, Demi̇rci̇oğlu S.   +4 more
europepmc   +1 more source

Cutaneous adverse effects of imatinib mesylate in phototype VI patients treated for chronic myeloid leukemia: Experience from Dakar, Senegal about 60 patients [PDF]

, 2023
Ly F, Nasser Odah, El Haiba H, Faye BF, Saint Louis, B. Seck, D. Zambo ́n, Moussa Seck, A Diop, Macoura Gadji, Gueye YB, Abibatou Sall, Touré Ao, Saliou Diop   +13 more
openalex   +1 more source

Results of TETimaX Trial of Langerhans Cell Histiocytosis Treatment and Perspectives on the Role of Imatinib Mesylate in the Era of MAPK Signaling. [PDF]

Biomedicines, 2021
Montella L, Ottaviano M, Riccio V, Picozzi F, Facchini G, Insabato L, Giuliano M, Palmieri G.   +7 more
europepmc   +1 more source

A Phase II Study of Imatinib Mesylate in Prostate Cancer Patients With Evidence of Biochemical Relapse Following Definitive Radical Retropubic Prostatectomy or Radiation Therapy [PDF]

, 2005
Gopal Bajaj, Elizabeth Garret-Mayer, Zhi Zhang, R. Drew, Victoria J. Sinibaldi, M. Gaver, Роберто Пили, Samuel R. Denmeade, Michael A. Carducci, William G. Nelson, Mario A. Eisenberger, Theodore L. DeWeese   +11 more
openalex   +1 more source

In vivo Pharmacokinetics and in vitro Release of Imatinib Mesylate-Loaded Liposomes for Pulmonary Delivery. [PDF]

Int J Nanomedicine, 2021
Xu H, Ji H, Li Z, Qiao W, Wang C, Tang J.   +5 more
europepmc   +1 more source

Nail lichen planus associated with imatinib mesylate. [PDF]

JAAD Case Rep
Axler E, Loesch E, Vaidya T, Neubauer Z, Lipner SR.   +4 more
europepmc   +1 more source

Imatinib Mesylate for the Treatment of Canine Mast Cell Tumors: Assessment of the Response and Adverse Events in Comparison with the Conventional Therapy with Vinblastine and Prednisone. [PDF]

Cells, 2022
Macedo TR, de Queiroz GF, Casagrande TAC, Alexandre PA, Brandão PE, Fukumasu H, Melo SR, Dagli MLZ, Pinto ACBCF, Matera JM.   +9 more
europepmc   +1 more source